Alaunos Therapeutics Financials - Benzinga

Alaunos Therapeutics Inc

TCRTNASDAQ

Trade with Public

Trade with Public

$1.76

-0.03-1.68%

At close: Aug 25, 5:00 PM EST

$1.52

-0.27-15.08%

Pre-Market: 8:03 AM EST

Overview News Earnings ForecastFinancialsSentiment Ownership Compare Stock Report

Alaunos Therapeutics Financials

Alaunos Therapeutics (TCRT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Alaunos Therapeutics Q2 EPS $(0.63) Up From $(0.71) YoY

Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.63) per share. This is a 11.27 percent increase over losses of $(0.71) per share from the same period last year.

Benzinga Newsdesk

Recap: Alaunos Therapeutics Q3 Earnings

Benzinga Insights

PRO
Alaunos Therapeutics Q3 EPS $(0.04), Same As Last Year

Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.04) per share. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Alaunos Therapeutics Q2 EPS $(0.04), Inline

Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.05) per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For May 10, 2023

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.

Benzinga Insights

PRO
Alaunos Therapeutics Q1 EPS $(0.04), Inline

Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.05) per share from the same period last year.

Benzinga Newsdesk